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Association of Vitamin A and Carotenoid Intake
with Melanoma Risk in a Large Prospective Cohort
Maryam M. Asgari1,2, Theodore M. Brasky3,4 and Emily White3,4
Laboratory data suggest that intake of vitamin A and carotenoids may have chemopreventive benefits against
melanoma, but epidemiological studies examining the association have yielded conflicting results. We
examined whether dietary and supplemental vitamin A and carotenoid intake was associated with melanoma
risk among 69,635 men and women who were participants of the VITamins And Lifestyle (VITAL) cohort study in
western Washington. After an average of 5.84 years of follow-up, 566 incident melanomas were identified.
Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence
intervals (CIs) for risk of melanoma associated with dietary, supplemental, and total vitamin A and carotenoid
intake after adjusting for melanoma risk factors. Baseline use of individual retinol supplements was associated
with a significant reduction in melanoma risk (HR: 0.60; 95% CI: 0.41–0.89). High-dose (41,200 mg per day)
supplemental retinol was also associated with reduced melanoma risk (HR: 0.74; 95% CI: 0.55–1.00), as compared
with non-users. The reduction in melanoma risk was stronger in sun-exposed anatomic sites. There was no
association of melanoma risk with dietary or total intake of vitamin A or carotenoids. Retinol supplementation
may have a preventative role in melanoma among women.
Journal of Investigative Dermatology (2012) 132, 1573–1582; doi:10.1038/jid.2012.21; published online 1 March 2012
INTRODUCTION
Melanoma is the sixth most common form of cancer in
the United States (American Cancer Society Fact and
Figures, 2010) and its lifetime incidence is rising (StatBite,
2011). It is estimated that 1 out of every 45 Americans
born in 2010 will be diagnosed with melanoma during
their lifetime (American Cancer Society Fact and Figures,
2010). The rising incidence of melanoma and its poor
prognosis in advanced stages (Criscione and Weinstock,
2010) are compelling reasons to identify new chemopreven-
tive agents. There is accumulating evidence that vitamin A
and its derivatives may have a chemoprotective role in
melanoma.
Vitamin A (retinol) is a fat-soluble, organic compound that
cannot be synthesized by humans, yet it is necessary for
normal physiological function, and thus it is classified as an
essential nutrient. Retinol belongs to a class of compounds
called retinoids that includes the naturally occurring relatives
of retinol, retinaldehyde, and retinoic acid, as well as over
1,000 synthetic compounds (van Berkel et al., 2009). The
main source of vitamin A in the diet is from retinyl esters,
mostly from animal products such as eggs, milk, and liver,
as well as from plant-based pro-vitamin A carotenoids
(a-carotene, b-carotene, b-cryptoxanthin) that can be con-
verted to retinol in the intestine. Carotenoids constitute a
large group of over 563 compounds (http://ods.od.nih.gov/
factsheets/VitaminA-HealthProfessional, accessed 11 August
2011), fewer than 10% of which can be converted to
vitamin A. The vast majority of carotenoids is non-
pro-vitamin A, and includes substances such as lutein,
zeaxanthin, and lycopene.
Retinoids have powerful effects on cell differentiation and
proliferation and inhibit malignant transformation (Goodman,
1984). They have been shown to inhibit the proliferation of
human melanoma cell lines (Meyskens and Salmon, 1979;
Meyskens and Fuller, 1980; Niu et al., 2005) and have been
shown to inhibit tumor invasion using in vitro models (Wood
et al., 1990). In vivo, murine models have shown that
retinoids decrease tumor size and improve survival from
melanoma (Weinzweig et al., 2003; Liu et al., 2008). The
pro-vitamin A carotenoids have also been shown to exert
antimelanoma activity through alternate pathways, including
antiangiogenic effects by altering cytokine profiles and
nuclear translocation of transcription factors in melanoma
cell lines (Palozza et al., 2003; Guruvayoorappan and Kuttan,
2007). Some non-pro-vitamin A carotenoids have also been
shown to have chemopreventive effects in vitro (Philips et al.,
2007).
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Epidemiological studies on the association of vitamin
A/carotenoid intake and melanoma risk have largely
been case–control studies and have yielded mixed results
(Osterlind et al., 1988; Stryker et al., 1990; Bain et al., 1993;
Kirkpatrick et al., 1994; Millen et al., 2004; Naldi et al.,
2004; Vinceti et al., 2005; Le Marchand et al., 2006). A
recently published systematic review and meta-analysis of
randomized controlled trials found no association between
b-carotene use and melanoma risk (relative risk (RR)¼0.98;
95% confidence interval (CI): 0.65–1.46) (Druesne-Pecollo
et al., 2010). These findings were supported by previously
published data using the VITamins And Lifestyle (VITAL)
cohort (RR: 0.87; 95% CI: 0.48–1.56) (Asgari et al., 2009). In
contrast to the lack of association noted with b-carotene use
and melanoma risk, data from a large prospective study using
two Nurses’ Health Study cohorts of women found that retinol
intake from foods plus supplements appeared protective within
a subgroup of low-risk participants (RR¼0.39; 95% CI:
0.22–0.71) (Feskanich et al., 2003). Thus, b-carotene and
retinol appear to have differential effects on melanoma risk.
We sought to explore the association between melanoma
risk and dietary, supplemental, and total intake of retinol and
carotenoids (including b-carotene, lutein, and lycopene)
using the VITAL cohort, the only large prospective study
specifically designed to investigate the association between
dietary supplements and cancer risk.
RESULTS
The average age of participants was 62 years (range: 50–76),
and slightly more than half of the participants were women
(52%). Most individuals had some college or an advanced
degree (80%) and were overweight or obese (63%). Cohort
members who developed primary cutaneous melanoma
during the follow-up period were more likely to be men, to
have attained higher education, and to have fair-skin
phenotype (childhood freckling,X3 severe sunburns, natural
red or blond hair, and have a tendency to burn with exposure
to sunlight) (Table 1). They were also more likely to have
had a personal history of skin cancer, a family history of
melanoma, and have had moles removed. Cases and non-
cases did not significantly differ in risk of a common
indication for vitamin A supplementation, namely history of
macular degeneration.
Of the 566 incident melanomas, there were 257 in situ
and 309 invasive tumors. The breakdown of histopathologi-
cal subtype of the invasive tumors was n¼ 144 melanomas
not otherwise specified, n¼88 superficial spreading, n¼38
lentigo maligna, n¼ 21 nodular, and n¼13 rare subtypes
(including five melanomas arising in a junctional nevus, four
spindle cell, three acral lentiginous, and one desomplastic
melanoma). There were five cases who had no information
on the subtype available. There were only 16 invasive
melanomas that developed among supplement users; there-
fore, our cell sizes for the subtype variable were too small to
permit meaningful analysis of supplement use by melanoma
histopathological subtype.
The results of supplement and dietary intake of retinol,
b-carotene, total vitamin, lutein, and lycopene and associated
melanoma risk are shown in Table 2. Relative to non-use,
current (hazard ratio (HR): 0.60; 95% CI: 0.41–0.89) but not
former (HR: 0.90; 95% CI: 0.57–1.43) use of individual retinol
supplements at baseline was associated with a decreased
risk for melanoma. Intake of supplemental retinol greater than
the amount that can be obtained from common multivitamin
formulations (41,200mg per day) was of borderline statistical
significance (HR: 0.74; 95% CI: 0.55–1.00); however, the
association was not linear (P-trend¼ 0.25). Retinol intake from
food and the combination of supplement and dietary intake
were not associated with melanoma risk.
b-Carotene, whether from supplement use or dietary
intake, was not associated with melanoma risk. Similarly,
total vitamin A intake and intake of pro-vitamin A carotenoids
were also not associated with melanoma risk. Among
participants who used individual lutein or lycopene supple-
ments, very few developed melanoma (no10); thus, our
cohort was underpowered to detect an association with
regard to supplemental intake of the non-pro-vitamin A
carotenoids. Although there was a trend for increased
melanoma risk with dietary intake of lutein, the effect was
no longer statistically significant in adjusted models of dietary
intake of the non-proretinoid carotenoids.
In examining the associations between retinol use and
melanoma risk stratified by gender (Table 3), the association
of current use of retinol supplements was largely driven by a
marked risk reduction in melanoma risk among women
(HR: 0.27; 95% CI: 0.11–0.66) but not among men (HR: 0.83;
95% CI: 0.54–1.27; P-interaction¼ 0.64). Inverse associ-
ations for high doses of retinol supplements and melanoma
were similar among men (HR: 0.77; 95% CI: 0.53–1.12) and
women (HR: 0.71; 95% CI: 0.43–1.16), although neither
achieved statistical significance. Similar to unstratified find-
ings, there were no clear associations or differences by
gender for retinol exposure from diet or total retinol,
irrespective of source (data not shown).
Table 4 shows the association of retinol supplement use
with melanoma by anatomic site. In comparing current users
to non-users, the reduction in melanoma risk with retinol use
appeared to be stronger in sun-exposed areas such as the
limbs (HR: 0.44; 95% CI: 0.22–0.89) and the head and neck
(HR: 0.49; 95% CI: 0.21–1.10) as compared with the trunk
(HR: 0.94; 95% CI: 0.52–01.70).
We examined the association between retinol (both
current use and dose) and tumor invasiveness and Breslow
depth as proxies for tumor progression (Table 5). In com-
paring in situ to invasive melanomas, or invasive melanomas
with Breslow depth o1.0mm to those 41.0mm, there was
no differential association with retinol use. With regard to
dose, low-dose users appeared to have a slightly increased
risk of thin (o1.0mm) melanoma as compared with non-
users (HR: 1.44; 95% CI: 1.04–2.00); however, this mildly
increased risk in low-dose retinol users did not manifest for
thicker melanomas (41.0mm).
DISCUSSION
In this prospective study, we found an inverse association
between supplemental intake of retinol and melanoma risk.
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The risk reduction was statistically significant for current
supplemental retinol users and was not significant for
former users (as compared with non-users). The association
remained stable after adjusting for age and gender, as well
as for melanoma-specific risk factors. The association was
largely driven by a marked risk reduction in women, whereas
the risk reduction in men did not achieve statistical
significance. The underlying reason for the differential effect
by gender may be by chance (spurious association); however,
gender differences in melanoma outcomes, with women
having more favorable outcomes, have been previously
reported (Scoggins et al., 2006).
Multivariable adjustment of the association between dose
of supplemental retinol and melanoma risk revealed that the
risk reduction was borderline significant only for high-dose
Table 1. Associations between baseline characteristics
and melanoma risk among VITAL participants
(n=69,635)
Characteristic
Cases
(n=566),
n (%)
Non-cases
(n=69,069),
n (%)
Age- and
gender-adjusted
HR (95% CI)
Demographics
Age at baseline (years)
50.0–54.9 102 (18.0) 15,990 (23.2) N/A
55.0–59.9 104 (18.4) 15,724 (22.8)
60.0–64.9 103 (18.2) 12,589 (18.2)
65.0–69.9 107 (18.9) 11,392 (16.5)
70.0–76.0 150 (26.5) 13,374 (19.4)
Gender1
Female 212 (37.5) 35,884 (52.0) 1.00 (reference)
Male 354 (62.5) 33,185 (48.1) 1.82 (1.54–2.16)
Education
pHigh school graduate 79 (14.0) 13,932 (20.2) 1.00 (reference)
Some college 179 (31.7) 26,348 (38.2) 1.29 (0.99–1.68)
College or advanced degree 307 (54.3) 28,624 (41.5) 1.93 (1.50–2.49)
P-trend o0.0001
Personal characteristics
Body mass index (kgm2)
o25.0 204 (36.9) 22,817 (34.3) 1.00 (reference)
25.0–29.9 255 (46.1) 27,400 (41.1) 0.94 (0.78–1.13)
X30.0 94 (17.0) 16,406 (24.6) 0.65 (0.41–0.83)
P-trend o0.01
Alcohol (drinks per day)
0 127 (22.6) 19,276 (28.3) 1.00 (reference)
o1 268 (47.8) 32,496 (47.8) 1.19 (0.96–1.48)
1–1.9 85 (15.2) 8,419 (12.4) 1.33 (1.01–1.76)
X2 81 (14.4) 7,866 (11.6) 1.28 (0.97–1.70)
P-trend 0.05
Energy intake (kcal per day)
0–1,287.7 109 (20.7) 15,961 (25.0) 1.00 (reference)
1,287.8–1,728.6 126 (23.9) 15,942 (25.0) 1.04 (0.81–1.35)
1,728.7–2,293.7 139 (26.4) 15,932 (25.0) 1.01 (0.78–1.32)
X2,293.8 153 (29.0) 15,917 (25.0) 1.00 (0.76–1.31)
P-trend 0.89
Freckles between ages 10 and 20 years
No 369 (65.9) 54,065 (79.0) 1.00 (reference)
Yes 191 (34.1) 14,383 (21.0) 2.15 (1.80–2.56)
Had X3 severe sunburns between ages 10 and 20 years
No 312 (55.7) 45,669 (66.9) 1.00 (reference)
Yes 248 (44.3) 22,553 (33.1) 1.67 (1.41–1.97)
Natural red or blond hair between ages 10 and 20 years
No 310 (55.1) 46,498 (67.9) 1.00 (reference)
Yes 253 (44.9) 22,026 (32.1) 1.78 (1.50–2.10)
Table 1. Continued
Characteristic
Cases
(n=566),
n (%)
Non-cases
(n=69,069),
n (%)
Age- and
gender-adjusted
HR (95% CI)
Reaction to 1 h in strong sunlight
Tan/no sunburn 37 (6.7) 8,345 (12.6) 1.00 (reference)
Mild sunburn then tan 241 (43.5) 32,084 (48.4) 1.75 (1.24–2.47)
Painful sunburn with
peeling
228 (41.2) 21,044 (31.8) 2.64 (1.86–3.74)
Severe sunburn with
blisters
48 (8.7) 4,815 (7.3) 2.54 (1.65–3.90)
P-trend o0.0001
Multivitamin use
Never 183 (32.3) 23,673 (34.3) 1.00 (reference)
Past 41 (7.2) 5,213 (7.6) 1.15 (0.82–1.61)
Current 342 (60.4) 40,173 (58.2) 1.16 (0.97–1.39)
Medical history
Number of first-degree relatives with melanoma
None 515 (92.0) 63,991 (93.9) 1.00 (reference)
1 41 (7.3) 3,860 (5.7) 1.43 (1.04–1.96)
X2 4 (0.7) 324 (0.5) 1.73 (0.65–4.62)
P-trend 0.02
History of non-melanoma skin cancer
No 456 (80.6) 63,836 (92.4) 1.00 (reference)
Yes 110 (19.4) 5,233 (7.6) 2.62 (2.12–3.23)
Had mole removed
No 327 (57.8) 50,734 (73.5) 1.00 (reference)
Yes 239 (42.2) 18,335 (26.6) 2.09 (1.76–2.46)
Macular degeneration
No 559 (98.8) 67,934 (98.4) 1.00 (reference)
Yes 7 (1.2) 1,120 (1.6) 0.67 (0.32–1.42)
Abbreviations: CI, confidence interval; HR, hazard ratio; NA, not applicable;
VITAL, VITamins And Lifestyle.
1Adjusted for age.
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Table 2. Associations between retinol and carotenoid intakes and melanoma risk among VITAL participants
(n=69,635)
Carotenoid
Cases (n=566),
n (%)
Non-cases (n=69,069),
n (%)
Age- and gender-adjusted
HR (95% CI)
Multivariable-adjusted
HR (95% CI)1
Retinol
Individual supplement use
Non-user 506 (91.34) 59,557 (87.60) 1.00 (reference) 1.00 (reference)
Former 20 (3.61) 2,655 (3.91) 0.97 (0.62–1.52) 0.90 (0.57–1.43)
Current 28 (5.05) 5,776 (8.50) 0.58 (0.40–0.85) 0.60 (0.41–0.89)
Supplement dose2
Non-user 213 (38.45) 27,434 (40.35) 1.00 (reference) 1.00 (reference)
19.3–1,200 mg per day 279 (50.36) 30,303 (44.57) 1.22 (1.02–1.46) 1.13 (0.93–1.36)
41,200 mg per day3 62 (11.19) 10,246 (15.07) 0.82 (0.62–1.09) 0.74 (0.55–1.00)
P-trend 0.78 0.28
Diet (mg per day)4
p280.5 119 (22.58) 15,951 (25.02) 1.00 (reference) 1.00 (reference)
280.6–424.7 118 (22.39) 15,951 (25.02) 0.90 (0.70–1.17) 0.89 (0.68–1.18)
424.8–638.4 169 (32.07) 15,902 (24.94) 1.20 (0.94–1.52) 1.24 (0.94–1.63)
4638.4 121 (22.96) 15,948 (25.02) 0.81 (0.62–1.05) 0.85 (0.62–1.16)
P-trend 0.42 0.72
Total (mg per day)2,4
p514.2 126 (24.42) 15,694 (25.00) 1.00 (reference) 1.00 (reference)
514.3–1,324.3 127 (24.61) 15,693 (25.00) 0.96 (0.75–1.23) 1.00 (0.77–1.30)
1,324.3–1,771.4 147 (28.49) 15,673 (24.97) 1.13 (0.89–1.44) 1.10 (0.86–1.42)
41,771.4 116 (22.48) 15,704 (25.02) 0.85 (0.66–1.10) 0.84 (0.64–1.10)
P-trend 0.46 0.33
b-Carotene
Individual supplement use
Non-user 502 (90.29) 61,478 (90.04) 1.00 (reference) 1.00 (reference)
Former 24 (4.32) 3,256 (4.77) 0.95 (0.63–1.43) 0.87 (0.57–1.32)
Current 30 (5.40) 3,546 (5.19) 1.03 (0.72–1.49) 0.95 (0.64–1.40)
Supplement dose2
Non-user 237 (42.63) 31,802 (46.58) 1.00 (reference) 1.00 (reference)
6.4–600 mg per day 200 (35.97) 22,933 (33.59) 1.20 (0.99–1.44) 1.16 (0.95–1.41)
4600 mg per day3 119 (21.40) 13,542 (19.83) 1.19 (0.95–1.48) 1.08 (0.86–1.36)
P-trend 0.08 0.36
Diet (mg per day)4
p2,138.8 103 (19.54) 15,967 (25.05) 1.00 (reference) 1.00 (reference)
2,138.9–3,504.9 136 (25.81) 15,933 (24.99) 1.22 (0.95–1.58) 1.15 (0.87–1.51)
3,505–5,648.5 137 (26.00) 15,934 (24.99) 1.16 (0.90–1.50) 1.07 (0.81–1.42)
45,648.5 151 (28.65) 15,918 (24.97) 1.25 (0.97–1.61) 1.15 (0.87–1.53)
P-trend 0.15 0.46
Total (mg per day)2,4
p3,515.0 101 (19.46) 15,277 (24.23) 1.00 (reference) 1.00 (reference)
3,515.1–6,117.7 134 (25.82) 16,276 (25.81) 1.19 (0.92–1.54) 1.17 (0.89–1.53)
6,117.8–9,358.2 144 (27.75) 15,750 (24.98) 1.27 (0.98–1.64) 1.16 (0.89–1.53)
49,358.2 140 (26.97) 15,754 (24.98) 1.22 (0.94–1.57) 1.13 (0.86–1.49)
P-trend 0.13 0.47
Table 1 continued on the following page
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Table 2. Continued
Carotenoid
Cases (n=566),
n (%)
Non-cases (n=69,069),
n (%)
Age- and gender-adjusted
HR (95% CI)
Multivariable-adjusted
HR (95% CI)1
Total vitamin A
Supplement dose2
Non-user 211 (38.22) 26,934 (39.82) 1.00 (reference) 1.00 (reference)
19.3–1,500RAE per day 273 (49.46) 31,387 (46.41) 1.15 (0.96–1.37) 1.06 (0.88–1.28)
41,500RAE per day3 68 (12.32) 9,310 (13.77) 0.97 (0.74–1.28) 0.88 (0.66–1.18)
P-trend 0.69 0.66
Diet (RAE per day)4
p574.4 105 (19.92) 15,965 (25.04) 1.00 (reference) 1.00 (reference)
574.5–822.3 140 (26.57) 15,930 (24.99) 1.22 (0.94–1.57) 1.25 (0.94–1.65)
822.4–1,176.6 135 (25.62) 15,935 (25.00) 1.09 (0.84–1.41) 1.07 (0.79–1.45)
41,176.6 147 (27.89) 15,922 (24.97) 1.12 (0.87–1.46) 1.16 (0.84–1.59)
P-trend 0.64 0.67
Total (RAE per day)2,4
p992.3 125 (24.27) 15,621 (25.01) 1.00 (reference) 1.00 (reference)
992.4–1,984.4 114 (22.14) 15,632 (25.02) 0.88 (0.68–1.13) 0.91 (0.70–1.19)
1,984.5–2,679.6 151 (29.32) 15,595 (24.96) 1.16 (0.91–1.47) 1.10 (0.85–1.41)
42,679.6 125 (24.27) 15,621 (25.01) 0.92 (0.72–1.18) 0.87 (0.66–1.13)
P-trend 0.94 0.60
Lutein
Individual supplement use
Non-user 557 (98.58) 67,399 (97.69) 1.00 (reference) 1.00 (reference)
User 8 (1.42) 1,595 (2.31) 0.64 (0.32–1.28) 0.58 (0.27–1.23)
Diet (lutein+zeaxanthin) (mg per day)4
p1,449.2 94 (17.8) 15,975 (25.1) 1.00 (reference) 1.00 (reference)
1,449.3–2,295.8 123 (23.3) 15,948 (25.0) 1.20 (0.91–1.57) 1.07 (0.80–1.42)
2,295.9–3,683.8 mg/d 149 (28.3) 15,920 (25.0) 1.35 (1.04–1.75) 1.25 (0.94–1.66)
43,683.8 161 (30.6) 15,909 (25.0) 1.41 (1.09–1.83) 1.27 (0.95–1.70)
P-trend o0.01 0.07
Lycopene
Individual supplement use
Non-user 563 (99.47) 68,585 (99.36) 1.00 (reference) 1.00 (reference)
User 3 (0.53) 442 (0.64) 0.76 (0.25–2.37) 0.76 (0.24–2.37)
Diet (mg per day)4
p3,163.6 113 (21.4) 15,957 (25.0) 1.00 (reference) 1.00 (reference)
3,163.7–5,257.6 126 (23.9) 15,944 (25.0) 1.07 (0.83–1.38) 1.01 (0.77–1.33)
5,257.7–8,680.9 135 (25.6) 15,934 (25.0) 1.06 (0.82–1.37) 1.07 (0.81–1.42)
48,680.9 153 (29.0) 15,917 (25.0) 1.13 (0.87–1.46) 1.15 (0.86–1.53)
P-trend 0.38 0.31
Abbreviations: CI, confidence interval; HR, hazard ratio; RAE, retinol activity equivalents (1 RAE=1 mg all-trans retinol); VITAL, VITamins And Lifestyle.
1Adjusted for age, gender, education, body mass index, alcohol, freckles between the ages of 10 and 20 years, X3 severe sunburns between the ages of
10 and 20 years, red or blond hair between the ages of 10 and 20 years, reaction to 1 h in strong sunlight, family history of melanoma, history of
non-melanoma skin cancer, mole removed, and macular degeneration.
2Includes multivitamin sources.
3Greater than the amount of that nutrient that could be obtained from daily use of one pill of the multivitamin Centrum Silver (Wyeth, Madison, New Jersey).
4Multivariable models additionally adjusted for energy intake.
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supplemental retinol users (41,200mg per day). Retinol users
in the mid-dose category (19.3–1,200mg per day), who were
largely multivitamin users, did not experience a lower
reduction in melanoma risk. Thus, the effect appears to be
limited to retinol users who take retinol in doses in excess of
that available in a standard multivitamin. There was no clear
association of intake of retinol from food sources with
melanoma risk.
Intake of b-carotene (from supplements, diet, or total) was
not associated with melanoma risk. Given that the vitamin A
activity of b-carotene in foods is 1/12 that of retinol (Institute
of Medicine, 2000), the lack of association of melanoma risk
with b-carotene appears consistent with a high-dose retinol-
specific effect. Our findings of a lack of association of
melanoma risk with b-carotene are supported by a recently
published meta-analysis of randomized controlled trials that
reported no effect of b-carotene supplementation on mela-
noma risk (RR: 0.98; 95% CI: 0.6–1.46) (Druesne-Pecollo
et al., 2010), as well as our previously published findings
using the VITAL cohort (RR: 0.87; 95% CI: 0.48–1.56) (Asgari
et al., 2009).
Non-pro-vitamin A carotenoids, such as lutein and
lycopene, cannot be converted to retinol. We detected no
association with lycopene intake, but did find an inverse
association with dietary lutein intake and melanoma risk,
with higher lutein intake being associated with a higher
melanoma risk, a finding that was no longer statistically
significant in adjusted models. Dietary intake of lycopene has
previously been shown to be associated with a reduction in
melanoma risk, with individuals in the highest quintile of
lycopene intake having significantly reduced risk for mela-
noma as compared with the lowest quintile (Millen et al.,
2004). However, other studies have failed to find an
association between melanoma risk and lycopene intake
(Stryker et al., 1990), as well as serum lycopene levels
(Comstock et al., 1991; Breslow et al., 1995). The epidemiol-
ogy literature is also mixed with regard to the association of
melanoma risk with dietary lutein: one case–control study
reported nonsignificant increases in risk for women from
dietary lutein, and near significant increases in risk regardless
of gender for blood plasma levels of lutein (Le Marchand
et al., 2006), whereas another case–control study found a
dose-dependent risk reduction with dietary lutein (Millen
et al., 2004). The lack of association between melanoma risk
and intake of these non-pro-vitamin A carotenoids may have
been due to their inability to be converted to retinol, which is
the form that appears to be associated with melanoma risk
reduction.
Numerous case–control studies have investigated the
association of vitamin A intake and melanoma risk, and
have reported mixed findings (Osterlind et al., 1988; Stryker
et al., 1990; Bain et al., 1993; Kirkpatrick et al., 1994; Millen
et al., 2004; Naldi et al., 2004; Vinceti et al., 2005; Le
Marchand et al., 2006). Exposure data from these studies
were collected after case diagnosis, making these study
potentially vulnerable to recall bias (Austin et al., 1994).
Selection bias in case–control studies is also a concern. There
has been only one other published large prospective cohort
study examining the association of dietary intake of vitamin A
with melanoma risk. Upon examining 162,000 women with
more than 1.6 million person-years of follow-up, they
reported that retinol intake from diet plus supplements
appeared protective within a low-risk subgroup of women
(RR: 0.39; 95% CI: 0.22–0.71 for41,800 vs. 400mg per day)
Table 3. Interaction between retinol supplement use and gender in relation to melanoma risk among VITAL
participants (n=69,635)
Males Females
Supplement
Cases (n=354),
n (%)
Non-cases (n=33,185),
n (%)
HR
(95% CI)1
Cases (n=212),
n (%)
Non-cases (n=35,884),
n (%)
HR
(95% CI)1
Retinol
Individual supplement use
Non-user 318 (90.86) 29,249 (89.29) 1.00 (reference) 188 (92.16) 30,308 (86.03) 1.00 (reference)
Former 10 (2.86) 1,014 (3.10) 0.79 (0.41–1.53) 10 (4.90) 1,641 (4.55) 1.02 (0.54–1.94)
Current 22 (6.29) 2,494 (7.61) 0.83 (0.54–1.27) 6 (2.94) 3,282 (9.32) 0.27 (0.11–0.66)
Supplement dose2
Non-user 143 (40.86) 14,855 (45.36) 1.00 (reference) 70 (34.31) 12,579 (35.70) 1.00 (reference)
19.3–1,200 mg per day 171 (48.86) 13,480 (41.16) 1.17 (0.93–1.48) 108 (52.94) 16,823 (47.75) 1.05 (0.76–1.44)
41,200 mg per day3 36 (10.29) 4,417 (13.49) 0.77 (0.53–1.12) 26 (12.75) 5,829 (16.55) 0.71 (0.43–1.16)
P-trend 0.60 0.29
Abbreviations: CI, confidence interval; HR, hazard ratio; RAE, retinol activity equivalents (1 RAE=1 mg all-trans retinol); VITAL, VITamins And Lifestyle.
1Adjusted for age, education, body mass index, alcohol, freckles between the ages of 10 and 20 years,X3 severe sunburns between the ages of 10 and 20
years, red or blond hair between the ages of 10 and 20 years, reaction to 1 h in strong sunlight, family history of melanoma, history of non-melanoma skin
cancer, mole removed, and macular degeneration.
2Includes multivitamin sources.
3Greater than the amount of that nutrient that could be obtained from daily use of one pill of the multivitamin Centrum Silver (Wyeth, Madison, New Jersey).
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(Feskanich et al., 2003). Although they only reported diet and
total retinol intake (and not supplemental intake separately),
their significant results are limited to total (not dietary) intake,
suggesting that supplemental retinol was the key driver
behind their findings.
Our data suggest a possible interaction between supple-
mental retinol use and the anatomic site of melanoma, with
sun-exposed sites showing a stronger protective effect than
sun-protected sites. It may be that retinol’s effects may be
mediated by sunlight exposure. This intriguing possibility
warrants further exploration in future studies.
Strengths of this investigation include the availability of
baseline information on major potential confounding factors,
including constitutional, personal, and family skin cancer
history, as well as the prospective collection of information
thereby avoiding recall bias. Other advantages include
the relatively large number of melanoma cases and the
high percentage of supplement users recruited into this study.
The high test–retest reliability and validity of the VITAL
questionnaire in capturing supplement intake over the past
10 years have been documented previously (Satia-Abouta
et al., 2003).
There are several limitations to this study. We did not
measure serum retinol or carotenoid levels, although serum
levels of these fat-soluble vitamins are tightly regulated. In
addition, this study did not ascertain detailed information on
some known melanoma risk factors such as number of nevi;
therefore, there is the possibility of residual confounding. We
could not define the degree of potential residual confound-
ing, interaction, and variations of effect according to these
unmeasured variables, such as nevus categories. Further-
more, the lack of a clear dose–response relationship with
regard to retinol supplement use perhaps suggests that there
may be a threshold for the effect of supplemental retinol,
which we were underpowered to further explore. Alterna-
tively, high-dose retinol users may have practiced other
health-care behaviors that impacted melanoma risk, which
were unmeasured, such as sun-protective behaviors that
could have potentially confounded our results. Finally,
although cohort studies are not generally affected by selec-
tion bias (because cohort members cannot self-select on the
basis of both exposure and future outcome), it is possible that
the recruited cohort had certain characteristics, such as high
level of education, that may limit the ability to generalize our
findings.
In summary, our data, which are based on a large pros-
pective cohort, suggest that retinol intake from individual
supplements is associated with a reduction in risk for mela-
noma, especially among women. Our findings suggest that
vitamin A supplementation may hold promise as a chemo-
preventive agent for melanoma.
MATERIALS AND METHODS
Study population
Men and women, aged 50–76 years at baseline, who lived in the
13-country region of western Washington State covered by the
Surveillance, Epidemiology, and End Results (SEER) cancer registry,
were eligible to participate. Using names purchased from a
commercial mailing list, a baseline 24-page self-administered
questionnaire about lifestyle factors, health history, dietary intake,
supplement use, personal characteristics, and cancer risk factors
Table 4. Association of retinol supplement use with
melanoma by anatomic site among VITAL participants
(n=69,635)
Cases, n (%) HR (95% CI)1
Head (n=154)
Supplement use
Non-user 141 (94.00) 1.00 (reference)
Former 3 (2.00) 0.54 (0.17–1.71)
Current 6 (4.00) 0.49 (0.21–1.10)
Supplement dose2
Non-user 55 (36.67) 1.00 (reference)
19.3–1,200 mg per day 80 (53.33) 1.25 (0.88–1.79)
41,200 mg per day3 15 (10.00) 0.78 (0.44–1.39)
P-trend 0.85
Trunk (n=164)
Supplement use
Non-user 143 (88.82) 1.00 (reference)
Former 6 (3.73) 1.03 (0.45–2.33)
Current 12 (7.45) 0.94 (0.52–1.70)
Supplement dose2
Non-user 69 (42.86) 1.00 (reference)
19.3–1,200 mg per day 74 (45.96) 1.01 (0.72–1.41)
41,200 mg per day3 18 (11.18) 0.73 (0.43–1.25)
P-trend 0.36
Limbs (n=228)
Supplement use
Non-user 205 (91.93) 1.00 (reference)
Former 10 (4.48) 1.01 (0.51–1.97)
Current 8 (3.59) 0.44 (0.22–0.89)
Supplement dose2
Non-user 82 (36.77) 1.00 (reference)
19.3–1,200 mg per day 116 (52.02) 1.18 (0.87–1.59)
41,200 mg per day3 25 (11.21) 0.71 (0.44–1.16)
P-trend 0.47
Abbreviations: CI, confidence interval; HR, hazard ratio; VITAL, VITamins
And Lifestyle.
1Adjusted for age, gender, education, body mass index, alcohol, freckles
between the ages of 10 and 20 years, X3 severe sunburns between the
ages of 10 and 20 years, red or blond hair between the ages of 10 and
20 years, reaction to 1 h in strong sunlight, family history of melanoma,
history of non-melanoma skin cancer, mole removed, and macular
degeneration.
2Includes multivitamin sources.
3Greater than the amount of that nutrient that could be obtained from
daily use of one pill of the multivitamin Centrum Silver (Wyeth, Madison,
New Jersey).
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were mailed to 364,418 individuals between October 2000 and
December 2002. Of these, 77,719 were returned and deemed
eligible. Further details regarding study design, recruitment, and
study implementation have been published previously (White et al.,
2004). This study was approved by the Fred Hutchinson Cancer
Research Center Institutional Review Board. The Declaration of
Helsinki Principles were followed and subjects gave their written,
informed consent.
Participants were excluded if they reported a positive or missing
history of melanoma diagnosis at baseline (n¼ 1,558); were of non-
white race or did not report their race (n¼ 6,489); or for whom a
post-baseline diagnosis of melanoma was available only from the
death certificate (n¼ 2) without a date of diagnosis. Additional
exclusions were made for participants who were missing baseline
information on supplement use (n¼ 35), leaving 69,635 participants
available for study.
Supplement use
Participants reported intake of multivitamins and individual vitamin
supplements over the 10 years before baseline. For all supplement
questions, a close-ended format was used to inquire about current/
past use, frequency, duration over the previous 10 years, and usual
dose per day for individual supplements and brand or exact nutrient
formulation for multivitamins. Current dose (mg per day) of retinol and
b-carotene was computed as:
P
(dose per day) (days per week/7),
summed over multivitamin and individual supplement sources. Total
vitamin A from supplements was computed in retinol activity
equivalents per day (RAE) in which 1 RAE¼ 1mg all-trans retinol.
Total supplemental vitamin A in RAE was computed as current dose
(mg per day) from retinolþ 0.5 current dose (mg per day) from
b-carotene. Current doses of supplemental retinol, b-carotene, and
total vitamin A were categorized into non-use, any dose less than or
equal to the dose that could be ascertained from daily use of the
Table 5. Association of retinol supplement use with melanoma aggressiveness, among VITAL participants
(n=69,635)
In situ Invasive
Cases (n=257), n (%) HR (95% CI)1 Cases (n=309), n (%) HR (95% CI)1
Supplement use
Non-user 230 (92.00) 1.00 (reference) 276 (90.79) 1.00 (reference)
Former 8 (3.20) 0.81 (0.40–1.65) 12 (4.00) 0.99 (0.54–1.80)
Current 12 (4.80) 0.57 (0.32–1.02) 16 (5.26) 0.63 (0.37–1.06)
Supplement dose2
Non-user 103 (41.20) 1.00 (reference) 110 (36.18) 1.00 (reference)
19.3–1,200 mg day1 121 (48.40) 1.00 (0.76–1.31) 158 (51.97) 1.25 (0.97–1.62)
41,200 mg day1
3
26 (10.40) 0.66 (0.42–1.02) 36 (11.84) 0.83 (0.55–1.25)
P-trend 0.13 0.94
Breslow depth o1.0mm Breslow depth X1.0mm
Invasive cases (n=185), n (%) HR (95% CI)1 Invasive cases (n=82), n (%) HR (95% CI)1
Supplement use
Non-user 166 (89.73) 1.00 (reference) 78 (95.12) 1.00 (reference)
Former 9 (4.86) 1.14 (0.56–2.32) 2 (2.44) 0.68 (0.17–2.79)
Current 10 (5.41) 0.68 (0.36–1.29) 2 (2.44) 0.30 (0.07–1.23)
Supplement dose2
Non-user 64 (34.59) 1.00 (reference) 34 (41.46) 1.00 (reference)
19.3–1,200 mg day1 101 (54.59) 1.44 (1.04–2.00) 41 (50.00) 0.93 (0.57–1.53)
41,200 mg day1
3
20 (10.81) 0.83 (0.49–1.41) 7 (8.54) 0.50 (0.21–1.20)
P-trend 0.77 0.17
Abbreviations: CI, confidence interval; HR, hazard ratio.
1Adjusted for age, gender, education, body mass index, alcohol, freckles between the ages of 10 and 20 years,X3 severe sunburns between the ages of 10
and 20 years, red or blond hair between the ages of 10 and 20 years, reaction to 1 h in strong sunlight, family history of melanoma, history of non-melanoma
skin cancer, mole removed, and macular degeneration.
2Includes multivitamin sources.
3Greater than the amount of that nutrient that could be obtained from daily use of one pill of the multivitamin Centrum Silver (Wyeth, Madison, NJ).
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most commonly taken multivitamin supplement in the cohort
(Centrum Silver; Wyeth, Madison, New Jersey), and doses greater
than that could be ascertained from daily use of common
formulations of multivitamins alone (retinol: 41,200 mg per day;
b-carotene: 4600 mg per day; vitamin A: 41,500RAE per day).
Other pro-vitamin A carotenoids were not included because they are
not sold in individual supplement form.
Diet and other covariates
Diet over the last year was assessed by a food frequency
questionnaire that was an adaptation of food frequency question-
naires developed for the Women’s Health Initiative and other studies
(Kristal et al., 1997; Patterson et al., 1999). The food frequency
questionnaire captured intakes of 120 food and beverage items and
included adjustment questions on types of foods and preparation
techniques. The food frequency questionnaire analytic program is
based on nutrient values from the Minnesota Nutrient Data System.
We categorized retinol (mg per day), b-carotene (mg per day), and
total vitamin A (RAE per day) from diet and from total intake (diet
plus supplements) into quartiles. RAE from food was computed as
the sum of (mg per day retinol)þ (mg per day b-carotene/12)þ (mg per
day other pro-vitamin A carotenoids/24) (Dietary Reference Intake,
2002). Total lutein intake was calculated as the sum of dietary
luteinþ zeaxanthin.
The remaining parts of the questionnaire ascertained participants’
demographic characteristics, health history, social history (including
tobacco and alcohol use), medication use, and cancer risk factors.
From these data we calculated body mass index (kgm2). Common
melanoma risk factors were also ascertained, including freckles
and hair color during ages 10–20 years, sun sensitivity, history
of sunburns, family history of melanoma, personal history of non-
melanoma skin cancer, and mole removal.
Melanoma ascertainment
Cohort members were followed up for incident melanoma diagnoses
from baseline to 31 December 2007. Melanomas were identified
through annual linkage of the VITAL cohort database to the western
Washington SEER cancer registry, which is maintained by the Fred
Hutchinson Cancer Research Center. All incident cancer cases,
except non-melanoma skin cancer, diagnosed within the 13-county
area of western Washington State are reported to SEER along with
stage, histology, and other tumor characteristics. Between baseline
and December 2007, 566 incident cases of melanoma were
diagnosed among eligible participants. These included 257 cases
of melanoma in situ and 309 cases of invasive melanoma.
We ascertained histopathological subtype and anatomic location
of the melanomas from the SEER database. The anatomic melanoma
location was derived from the SEER ICD-O topography codes to
create summary location variables as follows: (1) skin of the head,
neck, and face (including skin of the lip and external ear) (ICD-O
44.0–44.4): n¼ 154; (2) skin of the trunk (ICD-O 44.5): n¼ 164; and
(3) skin of the upper and lower limbs (ICD-O 44.6–44.7): n¼ 228.
Melanomas arising from the eye, nasal cavity, and unspecified areas
(i.e., skin NOS) were excluded.
Follow-up for censoring
Excluding the 0.8% of the cohort with incident melanoma diagnoses,
the remaining participants were right-censored from the analysis at
the earliest date of the following events: withdrawal from the study
(0.03%); death (5.7%); emigration from the 13-county SEER
catchment area (5.5%); or the end of follow-up on 31 December
2007 (88.7%). Deaths occurring in the cohort in Washington State
were ascertained by linkage of the VITAL cohort database to the
Washington State death file. Emigrations out of the SEER catchment
area were identified by linkage to the National Change of Address
System and by active follow-up by telephone calls and mailings.
Statistical analysis
Cox proportional hazards models were used to estimate multi-
variable-adjusted HRs and 95% CI for retinol and carotenoid intake
and melanoma risk. Age was treated as the time variable with
participants entering regression models at their baseline age and
exiting at their age at melanoma diagnosis or censor date. All
reported P-values are two-sided. P-values for trend (P trend) were
calculated by treating categorical exposures as ordinal in propor-
tional hazards models. We tested the proportionality assumption of
regression models; no model violated the assumption.
We selected a priori potential confounders including known
or suspected melanoma risk factors. Multivariable models were
adjusted for age at baseline (years), gender (female, male), education
(high school or less, some college, advanced degree), body mass
index (kgm2: o25.0, 25.0–29.9, X30.0), alcohol consump-
tion (drinks per day: 0, o1, 1–1.9, X2), first-degree family history
of melanoma (no, yes), personal history of non-melanoma skin
cancer (no, yes), ever had moles removed (no, yes), freckles
between ages 10 and 20 years (no, yes), had X3 severe sunburns
between ages 10 and 20 years (no, yes), natural red/blond
hair between ages 10 and 20 years (no, yes), and reaction to
exposure to strong sunlight for 1 hour (tan or no sunburn, mild
burning, painful sunburn, severe sunburn with blistering). Analyses
of micronutrients from diet or supplements plus diet were
additionally adjusted for energy intake (kcal per day, quartiles).
Because vitamin A, lutein, and lycopene supplements are marketed
for eye health, all models were additionally adjusted for history of
macular degeneration.
To assess whether differences in etiology exist in the association
between vitamin A exposures and melanoma risk, we stratified
models on gender, tumor invasiveness (in situ vs. invasive), and
Breslow depth (available for n¼ 272 invasive cases, o0.75 vs.
X0.75mm) as a proxy for tumor progression. All statistical analyses
were performed using SAS, version 9.1 (SAS Institute, Cary, North
Carolina).
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